SCHEMBL605200

SCHEMBL605200

CC(C)(C)C(=O)NCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
CNR1 P21554 1/20 0.41
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
DRD2 P14416 2/20 0.36
DRD4 P21917 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTGS1 P23219 1/20 0.35
KCNH2 Q12809 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16316312 0.86 POLB (0.50) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL2025563 0.85 POLB (0.52) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL3123112 0.84 ALDH1A1 (0.42) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL12565674 0.84 ALDH1A1 (0.42) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL5542570 0.83 TDP1 (0.55) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL25590070 0.82 CNR1 (0.49) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL11519344 0.82 ALDH1A1 (0.41) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL11922844 0.81 TDP1 (0.58) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL18622113 0.81 POLB (0.57) POLBALDH1A1MAPTMEN1KMT2A
SCHEMBL9355210 0.81 POLB (0.57) POLBALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240193-A Preparation method of recyclable N-acylated polyaminoester 苏州大学 2024-06-25 CN claimed
CN-108699005-A 3- (carboxy ethyl) -8- amino -2- oxo -1,3- aza-spiros-[4.5]Decane derivative 格吕伦塔尔有限公司 2018-10-23 CN claimed
CN-121270779-A Amphiphilic block polymer, drug-loaded nanoparticle powder, drug-loaded hydrogel, preparation method and application 北京市春立正达医疗器械股份有限公司 2026-01-06 CN disclosed
CN-118240193-A Preparation method of recyclable N-acylated polyaminoester 苏州大学 2024-06-25 CN disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 US disclosed
CN-117440944-A Oxothiazonium ion-containing sulfonic acid derivative compounds as photoacid generators in resist applications 贺利氏电子化学品有限公司 2024-01-23 CN disclosed
CN-112469719-B Heterocondensed pyridone compounds and their use as IDH inhibitors 内尔维亚诺医疗科学公司 2024-01-23 CN disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 US disclosed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 EP disclosed
EP-0678500-A1 Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1995-10-25 EP disclosed
US-4391980-A FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS CIBA-GEIGY CORPORATION (US) 1983-07-05 US disclosed
EP-0007605-B1 A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR CIBA-GEIGY AG (CH) 1982-09-15 EP disclosed
US-4303637-A Medication indicated for ocular hypertension ALZA CORPORATION (US) 1981-12-01 US disclosed
US-4294966-A SALT FORMATION CIBA-GEIGY CORPORATION (US) 1981-10-13 US disclosed
EP-0007605-A1 A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor CIBA-GEIGY AG (CH) 1980-02-06 EP disclosed
US-4161530-A CYCLIC SUBSTITUTED AMINO ALCOHOL BETA-RECEPTOR-BLOCKING AGENT AND TRYPTOPHANE CIBA-GEIGY CORPORATION (US) 1979-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors IDH1, IDH2, IDH3A POLB 1098/4885ALDH1A1 305/4885MAPT 3614/4885
US-11771715-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB POLB 984/4885ALDH1A1 4484/4885MAPT 4190/4885
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 POLB 1569/4885ALDH1A1 3813/4885MAPT 2472/4885
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 POLB 632/4885ALDH1A1 4878/4885MAPT 682/4885
US-11766449-B2 Circular RNA compositions and methods RTCB, RNGTT, HNRNPAB POLB 899/4885ALDH1A1 4532/4885MAPT 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.